Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLZ-100 in breast cancer surgery
NCT02496065Phase 1Completed
- Sponsor
- Blaze Bioscience
- Start
- Jul 2015
- Primary completion
- Dec 2016
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tozuleristide in breast cancer, sponsored by Blaze Bioscience. Primary endpoint: Number of participants with adverse events at 7 days. Started Jul 2015; status: completed.
02
Drugs
tozuleristide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02496065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496065.